NASDAQ
11.12.25 | 21:49
1,090 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11. | Evogene übertrifft Gewinnerwartungen nach Restrukturierung trotz Umsatzrückgangs | 1 | Investing.com Deutsch | ||
| 20.11. | Evogene: EPS übertrifft Schätzungen um 0,12 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| 20.11. | Evogene GAAP EPS of -$0.31 beats by $0.10, revenue of $0.31M misses by $0.34M | 2 | Seeking Alpha | ||
| 20.11. | Evogene Reports Third Quarter 2025 Financial Results | 85 | PR Newswire | Conference call and webcast: today, November 20, 2025, 9:00 AM ET
Financial Highlights:
During the first nine months ending September 30, 2025, Evogene advanced... ► Artikel lesen | |
| 20.11. | Evogene Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.11. | Evogene Q3 2025 Earnings Preview | 1 | Seeking Alpha | ||
| 19.11. | What's Next: Evogene's Earnings Preview | 1 | Benzinga.com | ||
| 30.09. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.09. | Evogene Ltd. - 6-K, Report of foreign issuer | 10 | SEC Filings | ||
| 19.08. | Evogene Q2 2025: Kostensenkungen federn verfehlte Umsatz- und Gewinnziele ab | 3 | Investing.com Deutsch | ||
| 19.08. | Evogene GAAP EPS of -$0.85 misses by $0.22, revenue of $0.88M misses by $0.05M | 1 | Seeking Alpha | ||
| 19.08. | Evogene Reports Second Quarter 2025 Financial Results | 150 | PR Newswire | Conference call and webcast: today, August 19, 2025, 9:00 am ET
Financial Highlights:
The financial results for the first half of 2025 of Lavie Bio, a subsidiary... ► Artikel lesen | |
| 18.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08. | Preview: Evogene's Earnings | 1 | Benzinga.com | ||
| 12.08. | Evogene startet KI-gestützte Forschungskooperation mit Universität Tel Aviv zur Behandlung von Stoffwechselerkrankungen | 2 | Investing.com Deutsch | ||
| 12.08. | Evogene partners with Tel Aviv University to develop metabolic disease treatments | 2 | Investing.com | ||
| 11.08. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.07. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.06. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,85 | +0,06 % | Lungenkrebs-Präparat: Studiendaten schieben Biontech an | Die Aktie von BioNTech startet mit frischem Schwung in die Woche und verbucht bis zum Mittag ein Kursplus von gut drei Prozent. Auslöser sind ermutigende Studiendaten zu einem neuen Wirkstoffkandidaten... ► Artikel lesen | |
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,270 | -0,84 % | Wochenende-Spezial: Curevac-Aktie polarisiert - kommt am Montag die Überraschung? | ||
| MODERNA | 25,150 | +0,16 % | Nanexa AB: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments... ► Artikel lesen | |
| STRYKER | 302,70 | -0,16 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| BIOGEN | 148,20 | -0,10 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| CRISPR THERAPEUTICS | 47,400 | -1,66 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| REGENERON PHARMACEUTICALS | 625,40 | -0,98 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,800 | +2,27 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,391 | +1,93 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| INFLARX | 0,885 | -1,50 % | InflaRx N.V.: InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 | JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,800 | +1,46 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| EDITAS MEDICINE | 2,100 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen |
EVOGENE LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOGENE LTD finden Sie auf Wallstreet Online.